Himanshu Naik

Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus

Richard Furie, Victoria P. Werth, Joseph F. Merola et al. · Journal of Clinical Investigation · 2019 · 297 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus

Victoria P. Werth, Richard Furie, Juanita Romero‐Díaz et al. · New England Journal of Medicine · 2022 · 137 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +15

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of the GPR40 Agonist TAK‐875: Results From a Double‐Blind, Placebo‐Controlled Single Oral Dose Rising Study in Healthy Volunteers

Himanshu Naik, Majid Vakilynejad, Jingtao Wu et al. · The Journal of Clinical Pharmacology · 2011 · 88 citations

Medicine, Pharmacokinetics, Pharmacology +16

A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects With Type 2 Diabetes

Eckhard Leifke, Himanshu Naik, Jingtao Wu et al. · Clinical Pharmacology & Therapeutics · 2012 · 87 citations

Medicine, Pharmacokinetics, Pharmacology +14

Development and validation of a high-performance liquid chromatography–mass spectroscopy assay for determination of artesunate and dihydroartemisinin in human plasma

Himanshu Naik, Daryl J. Murry, Lee E. Kirsch et al. · Journal of Chromatography B · 2004 · 86 citations

Pharmacy, Pharmaceutical Analysis, Pharmacology +12